- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07863024
Safety and Efficacy Study in Adults With Advanced Solid Tumors Receiving REGN13089-M404-M2980, an Antibody-drug Conjugate That Targets MET Protein on Tumors
A Phase 1/2 Study of REGN13089-M404-M2980, a MET-targeting Antibody-Drug Conjugate in Adult Participants With Previously Treated Advanced Solid Tumors
This study will test a Regeneron drug called REGN13089-M404-M2980 ("study drug") to see if it can help treat previously treated, advanced solid tumors (tumors that have grown and spread to different areas of the body).
The study is focused on advanced cancers that have more of a protein called mesenchymal epithelial transition factor (MET) on the surface of their cells than usual. The study drug works by binding to MET on tumor cells and delivering chemotherapy directly into those cells. This may stop growth of the cancer cells and kill only the cancer cells and not the other normal tissues in your body. However, some of the chemotherapy may still affect the normal cells and side effects can still occur.
The study is looking at:
- What side effects the study drug might cause
- How well the study drug works
- How much of the study drug is in the blood at different times
- If the body reacts to the study drug, in a way that may cause the study drug to not work as well
- What is the best dose of the study drug for treating previously treated, advanced solid tumors
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 2
- Fase 1
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Clinical Trials Administrator
- Número de teléfono: 844-734-6643
- Correo electrónico: clinicaltrials@regeneron.com
Ubicaciones de estudio
-
-
North Carolina
-
Huntersville, North Carolina, Estados Unidos, 28078
- Reclutamiento
- Carolina BioOncology Institute
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Key Inclusion Criteria:
- Histologically confirmed cancer (non-small cell lung cancer (epidermal growth factor receptor mutant type or epidermal growth factor receptor mutant type), colorectal cancer, gastric/gastroesophageal junction cancer, uveal melanoma, papillary renal cell carcinoma, or clear cell renal cell carcinoma) that is at an advanced stage as described in the protocol
- Participants must not be candidates for curative surgery or radiation
- Participants are required to have exhausted all therapeutic options that are expected to provide meaningful clinical benefit, either through disease relapse, treatment refractory disease, or intolerance of the therapy as described in the protocol
- Willing to provide tumor tissue; archival or fresh tumor tissue will be accepted as described in the protocol
- At least 1 lesion that is measurable by RECIST 1.1. Tumor lesions in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions after radiation
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Adequate organ and bone marrow function as described in the protocol
Key Exclusion Criteria:
- Has received treatment with an approved systemic therapy or has participated in any study of an investigational agent or investigational device as described in the protocol
- Has received radiation therapy within the 28 days prior to first administration of study intervention. Palliative stereotactic radiation therapy without a thoracic or abdominal field is allowed with a washout period of 14 days from first administration of study intervention.
- Has undergone major surgery within the 14 days prior to first administration of study intervention
- Has not yet recovered (ie, grade ≤1 or baseline) from any acute toxicities resulting from prior therapy as described in the protocol
- Has a history of interstitial lung disease (eg, idiopathic pulmonary fibrosis, etc) or active, noninfectious pneumonitis that required immune-suppressive doses of glucocorticoids to assist with management or has imaging consistent with these diseases during the screening period. A history of radiation pneumonitis is permitted as long as pneumonitis resolved ≥6 months prior to enrollment.
- Has received prior treatment with an antibody-drug conjugate (ADC) that includes a topoisomerase payload
- Known active or untreated brain metastases or spinal cord compression. Participants are eligible if central nervous system (CNS) metastases are adequately treated, and participants have neurologically returned to baseline (except for residual signs or symptoms related to the CNS treatment) for at least 2 weeks prior to enrollment.
Note: Other protocol defined inclusion/ exclusion criteria apply
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación Secuencial
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Parte 1: Aumento de dosis
|
Administered per the protocol |
|
Experimental: Parte 2: Expansión de dosis
|
Administered per the protocol |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Occurrence of dose-limiting toxicities (DLTs)
Periodo de tiempo: Up to 21 days
|
Part 1 (Dose Escalation) |
Up to 21 days
|
|
Occurrence of Treatment Emergent Adverse Events (TEAEs)
Periodo de tiempo: Up to approximately 5 years
|
Part 1 (Dose Escalation) |
Up to approximately 5 years
|
|
Occurrence of Serious Adverse Events (SAEs)
Periodo de tiempo: Up to approximately 5 years
|
Part 1 (Dose Escalation) |
Up to approximately 5 years
|
|
Occurrence of adverse event of special interests (AESIs)
Periodo de tiempo: Up to approximately 5 years
|
Part 1 (Dose Escalation) |
Up to approximately 5 years
|
|
Objective response (OR) (investigator assessed) per Response Evaluation Criteria In Solid Tumors (RECIST) 1.1
Periodo de tiempo: Up to approximately 5 years
|
Part 2 (Dose Expansion) |
Up to approximately 5 years
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Objective response (investigator assessed) per RECIST 1.1
Periodo de tiempo: Up to approximately 5 years
|
Part 1 (Dose Escalation) |
Up to approximately 5 years
|
|
Concentrations of ADC
Periodo de tiempo: Up to approximately 5 years
|
Part 1 (Dose Escalation) and Part 2 (Dose Expansion) |
Up to approximately 5 years
|
|
Concentrations of total antibody
Periodo de tiempo: Up to approximately 5 years
|
Part 1 (Dose Escalation) and Part 2 (Dose Expansion) |
Up to approximately 5 years
|
|
Concentrations of payload (ProDXd and DXd)
Periodo de tiempo: Up to approximately 5 years
|
Part 1 (Dose Escalation) and Part 2 (Dose Expansion) |
Up to approximately 5 years
|
|
Occurrence of Anti-Drug Antibodies (ADA) against REGN13089-M404-M2980
Periodo de tiempo: Up to approximately 5 years
|
Part 1 (Dose Escalation) and Part 2 (Dose Expansion) |
Up to approximately 5 years
|
|
Magnitude of ADA against REGN13089-M404-M2980
Periodo de tiempo: Up to approximately 5 years
|
Part 1 (Dose Escalation) and Part 2 (Dose Expansion) |
Up to approximately 5 years
|
|
Duration of response per RECIST 1.1
Periodo de tiempo: Up to approximately 5 years
|
Part 2 (Dose Expansion) |
Up to approximately 5 years
|
|
Time to response per RECIST 1.1
Periodo de tiempo: Up to approximately 5 years
|
Part 2 (Dose Expansion) |
Up to approximately 5 years
|
|
Progression-free survival per RECIST 1.1
Periodo de tiempo: Up to approximately 5 years
|
Part 2 (Dose Expansion) |
Up to approximately 5 years
|
|
Overall survival
Periodo de tiempo: Up to approximately 5 years
|
Part 2 (Dose Expansion) |
Up to approximately 5 years
|
|
Occurrence of TEAEs considered clinically significant
Periodo de tiempo: Up to approximately 5 years
|
Part 2 (Dose Expansion) |
Up to approximately 5 years
|
|
Laboratory abnormalities considered clinically significant
Periodo de tiempo: Up to approximately 5 years
|
Part 2 (Dose Expansion) |
Up to approximately 5 years
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Director de estudio: Clinical Trial Management, Regeneron Pharmaceuticals
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
- NSCLC
- REUNIÓ
- Cáncer colonrectal
- Cáncer gástrico
- Cáncer de pulmón de células no pequeñas
- Cáncer avanzado
- Metastásico
- Irresecable
- Cáncer de la unión gastroesofágica
- Tumor sólido metastásico
- ADC
- Primero en humanos
- Melanoma uveal
- Conjugado anticuerpo-fármaco
- Carcinoma de células renales de células claras
- FIH
- Malignidad sólida avanzada
- Carcinoma papilar de células renales
- METxMET antibody-drug conjugate
- Solid neoplasm
- Unresectable solid tumor
Términos MeSH relevantes adicionales
- Enfermedades urogenitales
- Procesos Patológicos
- Neoplasias urogenitales
- Neoplasias por sitio
- Neoplasias
- Enfermedades urogenitales masculinas
- Enfermedades Renales
- Enfermedades urológicas
- Enfermedades urogenitales femeninas
- Enfermedades urogenitales femeninas y complicaciones del embarazo
- Enfermedades intestinales
- Enfermedades de las vías respiratorias
- Neoplasias por tipo histológico
- Neoplasias Gastrointestinales
- Neoplasias del Sistema Digestivo
- Enfermedades del Sistema Digestivo
- Enfermedades Gastrointestinales
- Enfermedades del Estómago
- Neoplasias Intestinales
- Enfermedades Rectales
- Enfermedades pulmonares
- Enfermedades de los ojos
- Neoplasias Glandulares y Epiteliales
- Adenocarcinoma
- Neoplasias de las vías respiratorias
- Neoplasias torácicas
- Enfermedades del Colon
- Procesos Neoplásicos
- Neoplasias Pulmonares
- Neoplasias Urológicas
- Carcinoma
- Tumores neuroectodérmicos
- Neoplasias De Células Germinales Y Embrionarias
- Neoplasias De Tejido Nervioso
- Neoplasias Renales
- Carcinoma Broncogénico
- Neoplasias Bronquiales
- Tumores neuroendocrinos
- Nevos y Melanomas
- Neoplasias Oculares
- Enfermedades uveales
- Melanoma
- Condiciones Patológicas, Signos y Síntomas
- Neoplasias uveales
- Neoplasias de Estómago
- Neoplasias colorrectales
- Metástasis de neoplasias
- Carcinoma De Célula Renal
- Carcinoma de pulmón de células no pequeñas
- Melanoma uveal
Otros números de identificación del estudio
- R13089-ONC-25128
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing
Marco de tiempo para compartir IPD
When Regeneron has:
- received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development
- made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry)
- the legal authority to share the data, and
- ensured the ability to protect participant privacy
Criterios de acceso compartido de IPD
Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
Tipo de información de apoyo para compartir IPD
- PROTOCOLO DE ESTUDIO
- SAVIA
- CIF
- CÓDIGO_ANALÍTICO
- RSC
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .